-
Celestial Biologics was approved by the CDE to conduct a Phase 3 registered clinical trial of lyzolizumab combined with azacitidine for the treatment of HR-MDS
Time of Update: 2022-09-21
/* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prnews
-
Data from the world's first phase III study of oral TYK2 allosteric inhibitor deuscravacitinib in Asian populations were released
Time of Update: 2022-09-21
13, 2022 /PRNewswire/ -- Bristol-Myers Squibb presented the results of the key Phase III study of POTYK PSO-3 at the recent 2022 European Society of Dermatology and Venereal Diseases Annual Meeting (EADV), confirming that in Asian patients with moderate to severe plaque psoriasis, mainly in China The world's first oral tyrosine kinase 2 (TYK2) allosteric inhibitor, deuscravacitinib, has significantly long-lasting benefits, is well tolerated for safety, and has also shown therapeutic advantages in refractory sites (scalp).
-
BeiGene released the latest data at the 2022 European Conference on Oncology, including the results of an oral report on the study of terelizumab for first-line unresectable hepatocellular carcinoma
Time of Update: 2022-09-21
/* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prnews
-
FWD announces the latest information and interim results on the bond consent solicitation
Time of Update: 2022-09-20
"Mr. Wong,"FWD adheres to the customer-first service concept, combining digital platforms and reliable distribution channels, and is committed to creating a new insurance experience for the public.
-
Chuangsheng Group's first clinical trial application for the treatment of solid tumors, the Gremlin1 antibody TST003, was approved by the US FDA
Time of Update: 2022-09-20
About Chuangsheng GroupChuangsheng Group is a clinically integrated biopharmaceutical company with comprehensive capabilities in biopharmaceutical discovery, R&D, process development and production.
About Chuangsheng GroupChuangsheng Group is a clinically integrated biopharmaceutical company with comprehensive capabilities in biopharmaceutical discovery, R&D, process development and production.
-
The latest type 2 diabetes medications reach blood sugar and weight goals faster
Time of Update: 2022-09-20
CI = confidence interval; HR = risk ratio; Encounter = metformin; SGLT2i = sodium/glucose cotransporter-2 inhibitor; TZP = tirzepatide; vs = and TZP 5 mgTZP 10 mgTZP 15 mgComparatorUltraserotonin with semiglutide 1 mg - added to METn = 470 (tzp5 mg), 469 (tzp 10 mg), 469 (tzp 15 mg), 468 (cima glucoside)*Glycosylated hemoglobin <53 mmol/mol (7%)Median time to first target reached (weeks)8.
-
Privat and FIND have reached a strategic partnership to jointly promote the development of women's health industries in low- and middle-income countries
Time of Update: 2022-09-14
(Privat) signed a cooperation agreement with the Global Innovative Diagnostic Foundation (FIND) to solve the lack of diagnostic tools for women's health care in low- and middle-income areas with the help of the Prima MiniDock molecular detection system, improve the overall detection and disease monitoring level in the region, and build a new generation of POC molecular detection ecosystem.
-
Maiwei Bio's innovative drug 6MW3511 injection was approved for clinical trials
Time of Update: 2022-09-10
SH), an innovative biopharmaceutical company with a full industrial chain layout, announced today that the clinical trial application for its self-developed 6MW3511 injection has been officially approved.
-
The Medtronic Donation Ceremony of Yunnan Youth Development Foundation "Yunfu Special Fund" was successfully held
Time of Update: 2022-09-10
prntac{ TEXT-ALIGN: CENTER } Join hands to do good deeds and bring "heart" hope to childrenKunming, Aug. 24, 2022 /PRNewswire/ -- In response to the healthy China 2030 strategic goals and encouraging more forces to help social welfare undertakings, on August 23, the "Yunfu Special Fund" sponsored by the Yunnan Youth Development Foundation "The Medtronic donation ceremony was successfully held in Kunming, Yunnan Province .
-
Proton Bio and Ruotai Announce Strategic Cooperation to Accelerate the Development of Bacterial Drugs and mRNA Drugs
Time of Update: 2022-09-10
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
-
Chaoshili was elected as the first member of the National Ophthalmology Standardization Technical Committee
Time of Update: 2022-09-09
The important purpose of the National Optometry Standardization Technical Committee is to organize representatives from universities, hospitals, inspection and testing centers, manufacturers, sales companies and other related industries in many places across the country to jointly be responsible for the management, terminology, products and equipment in the field of ophthalmology and optometry.
-
2022 International Rehabilitation Product Innovation (China) Competition Launched
Time of Update: 2022-09-09
7) The nominated team was invited to attend the SMILE AWARD awards dinnerWinning benefits1) The winning works will be awarded trophies and certificates by the Organizing Committee of the International Rehabilitation Product Innovation (China) Competition2) The winning works will be displayed in the SMILE AWARD work area on the site of the 2023 Shanghai International Rehabilitation Equipment and Solutions Exhibition (REHACARE SHANGHAI).
-
Asun Pharmaceutical Announces 2022 Interim Results: Nirick? Commercialization has accelerated, and key pipeline varieties have gradually entered the harvest period
Time of Update: 2022-09-09
The commercialization of Nelik ® has accelerated, and the clinical potential has been continuously tappedAs the first and only approved and marketed drug with T315I mutation chronic myeloid leukemia (CML) in China, Yasheng Pharmaceutical's core products, original class 1 new drugs, and national "major new drug creation" special achievements Nelik ® fills the domestic clinical gap and breaks the previous survival dilemma of patients with T315I mutation CML resistance, which has great value.
-
University of Hong Kong team finds a drug-resistant superbug can be severe or cause sepsis
Time of Update: 2022-09-09
According to Hong Kong Sing Tao. com, the Faculty of Medicine of the University of Hong Kong analyzed the clinical data of the Hong Kong Hospital Authority over the past 10 years and found that a drug-resistant superbug called CPE, "Carbapenemase-producing Enterobacter", was found in local hospitals.
-
MGI launched the IPO on the Science and Technology Innovation Board, planning to raise 2.528 billion yuan
Time of Update: 2022-09-09
R & D strength builds competition barriers Accelerated penetration of overseas markets As one of the few high-end manufacturers of clinical-grade sequencers in the world, MGI's continuous high R&D investment for many years is an important reason for the company's comparative advantage in competition with international giants, and it is also the company's long-term competitive position in the future.
-
Genting Sunyao Announces the Resignation of Dr. Blakely as Chief Executive Officer
Time of Update: 2022-09-09
About Genting SunyaoGenting Xinyao is a biopharmaceutical company focusing on the development and commercialization of innovative drugs, dedicated to meeting the unmet medical needs of the Asian market .
-
Shanghai Pharma Cloud Health's first domestic "Yiyao comprehensive flagship" landed in Xuhui, Shanghai
Time of Update: 2022-09-09
62em; font-family:"Arial"; color:black; margin:0in; } "Yiyao Comprehensive Flagship" realizes diversified services around out-of-hospital scenarios, helping global innovative drugs to reach Chinese patients fasterSHANGHAI, Aug. 26, 2022 /PRNewswire/ -- Shanghai Pharma Cloud Health announced that the opening ceremony of its first domestic "Yiyao Comprehensive Flagship" and the signing ceremony of its multi-party cooperation strategy were successfully completed in Xuhui, Shanghai .
-
Agilent Microplates are in stock, arrive faster, and have a free trial!
Time of Update: 2022-09-08
◇ Spot microplatesAgilent microplate series, high quality, good performance, our company has a variety of types of microplates in stock (deep well plate / sample tank / cell culture imaging, etc.
-
Fosun Pharma's Revenue and Recurring Income Grows Steadily in the First Half of 2022
Time of Update: 2022-09-08
92 percentage points year-on-year, and the global operation capability continued to improve;Revenue from new products and sub-new products, including Fubitai, Hanlikang, Hanquyou, Su Kexin, and Hansizuo, accounted for more than 25% of the revenue of the pharmaceutical business, and the product structure continued to be optimized .
-
BIOSAItu is listed on the main board of the Hong Kong Stock Exchange and aspires to become the birthplace of new drugs in the world
Time of Update: 2022-09-07
With the RenMiceTM platform as the core of the "Thousand Rats Anti-TM" program enables BIOSETU to target verification and antibody drug discovery of 1000+ potential new drug targets, with the help of 5 major technology platforms, BIOSETU can continue to produce highly potential antibody drug molecules, through cooperation with global pharmaceutical companies to develop / transfer development, is committed to becoming the birthplace of new drugs in the world.
